← Back to Screener
Dogwood Therapeutics, Inc. Common Stock (DWTX)
Price$1.50
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-84.92%
Price vs S&P 500 (4W)-9.08%
VGM Score19.94
Market Capitalization$50.44M
All Metrics
Book Value / Share (Quarterly)$2.52
P/TBV (Annual)20.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.53
Price vs S&P 500 (YTD)-72.10%
EPS (TTM)$-18.03
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-18.03
EPS (Annual)$-6.88
ROI (Annual)-45.74%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-37.99%
EBITD / Share (TTM)$-6.86
ROE (5Y Avg)-96.25%
Cash Flow / Share (Annual)$-0.53
P/B Ratio0.67x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-4,282,200
Net Interest Coverage (TTM)-99.42x
ROA (TTM)-36.46%
EPS Incl Extra (Annual)$-6.88
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)2.13x
3-Month Avg Trading Volume0.08M
52-Week Price Return-69.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.20
52-Week High$9.50
EPS Excl Extra (Annual)$-6.88
26-Week Price Return-76.99%
Quick Ratio (Annual)2.13x
13-Week Price Return-47.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.76x
Enterprise Value$43.92M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev97.41%
Net Income / Employee (TTM)$-4,282,200
ROE (Last FY)-45.74%
Net Interest Coverage (Annual)-50.78x
EPS Basic Excl Extra (Annual)$-6.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-18.03
ROI (TTM)-43.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.20
Price vs S&P 500 (52W)-93.66%
Year-to-Date Return-63.94%
5-Day Price Return-11.76%
EPS Normalized (Annual)$-6.88
ROA (5Y Avg)-85.15%
Month-to-Date Return-11.24%
EBITD / Share (Annual)$-6.85
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-96.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-18.03
P/TBV (Quarterly)20.92x
P/B Ratio (Annual)1.65x
Book Value / Share (Annual)$2.52
Price vs S&P 500 (13W)-55.81%
Beta1.76x
Revenue / Share (TTM)$0.00
ROE (TTM)-43.15%
52-Week Low$1.28
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.15est. -0.26
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DWTXDogwood Therapeutics, Inc. Common Stock | — | — | F | $1.50 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Dogwood Therapeutics (formerly Virios Therapeutics) is a development-stage biotech company developing antiviral therapies for conditions associated with abnormal viral-triggered immune responses, including fibromyalgia and long COVID. Its lead candidates—IMC-1, which targets Epstein-Barr virus replication, and IMC-2, a combination of valacyclovir and celecoxib—address the underlying immune dysfunction believed to drive these conditions.